GLP-1

GLP-1 receptor agonists and compounds studied primarily through the glucagon-like peptide-1 pathway. Showing 2 compounds.

← All categories
Semaglutide FDA-approved GLP-1 agonist studied in weight reduction, glycemic control, and cardiovascular outcomes. View research notes → Tirzepatide FDA-approved dual GIP/GLP-1 agonist with superior weight loss outcomes vs. semaglutide in trials. View research notes → Retatrutide Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a single-molecule agonist at three distinct hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. View research notes →